Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
|Podcasts|July 13, 2011
Examination with John T. Kissel, MD about Fibromyalgia [Podcast]
John T. Kissel, MD, Discusses how to diagnosis someone with Fibromyalgia
Advertisement
Interview with John T. Kissel, MD about Fibromyalgia; Director, Division of Neuromuscular Medicine Professor of Neurology at Ohio State University Medical Center.
Advertisement
Related to this article
Advertisement
Advertisement